GlassScriptPhysician profile
Abraham R Librea
NPI 1578119954
$5,245.74
in general payments reported to CMS, 2019-2025
42 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $724 · 2023: $1,414 · 2024: $1,284 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.50 | 2021-2025 | |
| Amgen INC. | $503.12 | 2021-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $445.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $413.20 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $353.80 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $330.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $260.89 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.84 | 2022-2025 | Jardiance |
| Abbott Laboratories | $186.95 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $168.04 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.41 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $112.11 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $91.24 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $82.45 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Nevro Corp. | $68.54 | 2023-2024 | Senza |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Librea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.